SPY343.38+1.37 0.40%
DIA282.95+0.92 0.33%
IXIC11,516.49+37.51 0.33%

VBL Therapeutics Announces Co. Granted European Patent, Which Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036

VBL Therapeutics (NASDAQ:VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat

· 10/12/2020 07:03

VBL Therapeutics (NASDAQ:VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

VBL has recently demonstrated ex-vivo activity of anti-MOSPD2 antibodies in patients with relapsing-remitting and progressive multiple sclerosis (MS), as well as in animal models of rheumatoid arthritis (RA), nonalcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD).

The claims in the granted patent cover the use of such an antibody/antibody fragment to treat a wide range of inflammatory and autoimmune conditions. The patent is expected to provide protection for VBL’s MOSPD2 antibodies for inflammation, until at least July 2036.

“With a completely novel mechanism that targets monocytes, we believe that our lead drug candidate can be a game changer in many chronic inflammatory diseases,” said Dror Harats, MD., Chief Executive Officer of VBL Therapeutics. “This patent provides intellectual property protection for our MOSPD2 platform technology, which is an important business advantage as we advance this program to enter the clinic in 2021.”

The Company recently held a pre-IND meeting with the FDA and has reached alignment with the Agency on the path forward for its lead anti-MOSPD2 candidate. A first-in-human study is planned to commence in the second half of 2021